Biocidal Products Committee (BPC)

Opinion on the application for approval of the active substance:

5-Chloro-2-(4-chlorophenoxy)-phenol (DCPP)

Product type: 2

ECHA/BPC/35/2014

Adopted

4 December 2014
Opinion of the Biocidal Products Committee

on the approval of the active substance DCPP for product type 2

In accordance with Article 89(1) of Regulation (EU) No 528/2012 of the European Parliament and of the Council 22 May 2012 concerning the making available on the market and use of biocidal products (BPR), the Biocidal Products Committee (BPC) has adopted this opinion on the approval in product type 2 of the following active substance:

- **Common name:** DCPP
- **Chemical name(s):** 5-Chloro-2-(4-chlorophenoxy)-phenol
- **EC No.:** 429-290-0
- **CAS No.:** 3380-30-1

**Existing active substance**

This document presents the opinion adopted by the BPC, having regard to the conclusions of the evaluating Competent Authority. The assessment report, as a supporting document to the opinion, contains the detailed grounds for the opinion.

**Process for the adoption of BPC opinions**

Following the submission of an application originally by Ciba Spezialitätenchemie Grenzach GmbH, in the context of the acquisition of Ciba by BASF, BASF SE continued to act as applicant. On 19 February 2013 the evaluating Competent Authority Austria submitted an assessment report and the conclusions of its evaluation to the Commission. In order to review the assessment report and the conclusions of the evaluating Competent Authority, the Agency organised consultations via the BPC and the Commission via the Biocides Technical Meetings. Revisions agreed upon were presented and the assessment report and the conclusions were amended accordingly.

Information on the fulfilment of the conditions for considering the active substance as a candidate for substitution was made publicly available at http://echa.europa.eu/addressing-chemicals-of-concern/biocidal-products-regulation/potential-candidates-for-substitution-previous-consultations/-/substance/5801/search/+term on 11 April 2014, in accordance with the requirements of Article 10(3) of Regulation (EU) No 528/2012. Interested third parties were invited to submit relevant information by 10 June 2014.

**Adoption of the BPC opinion**

**Rapporteur:** BPC Member for Austria

The BPC opinion on the approval of the active substance DCPP in product type 2 was adopted on 4 December 2014.

No comments were received from interested third parties during the public consultation in accordance with Article 10(3) of BPR.

The BPC opinion was adopted by consensus.
Detailed BPC opinion and background

1. Overall conclusion

The overall conclusion of the BPC is that the DCPP in product type 2 may be approved. The detailed grounds for the overall conclusion are described in the assessment report.

2. BPC Opinion

2.1. BPC Conclusions of the evaluation

a) Presentation of the active substance including the classification and labelling of the active substance

This evaluation covers the use of 5-Chloro-2-(4-chlorophenoxy)-phenol (common name: DCPP) in product type 2. DCPP has several mechanisms of action including membrane destabilization, inhibition of fatty acid synthesis. Specifications for the reference source are established.

The physico-chemical properties of the active substance and biocidal product have been evaluated and are deemed acceptable for the appropriate use and materials suitable for storage and transport of the active substance and biocidal product.

Validated analytical methods are available for the active substance as manufactured and for the relevant and significant impurities. Validated analytical methods are required and available for the relevant matrices soil and water.

DCPP is structurally closely related to the antibacterial active substance triclosan. The evaluation is partially based on read across from triclosan to DCPP.

A harmonised classification is available: Eye Damage, Category 1, (H318 – causes serious eye damage), Aquatic Acute 1 (H400 - Very toxic to aquatic life) and Aquatic Chronic 1 (H410 - Very toxic to aquatic life with long lasting effects).

A CLH dossier was submitted to ECHA on 5 July 2013 to include M-Factors for acute and chronic environmental classification.

The classification and labelling for DCPP according to Regulation (EC) No 1272/2008 (CLP Regulation) including the Austrian proposal regarding the M-Factor for Environment hazards is:

<table>
<thead>
<tr>
<th>Classification according to the CLP Regulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hazard Class and Category Codes</td>
</tr>
<tr>
<td>Eye damage, Category 1</td>
</tr>
<tr>
<td>Aquatic Acute 1</td>
</tr>
<tr>
<td>Aquatic Chronic 1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Labelling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pictograms</td>
</tr>
<tr>
<td>GHS 05</td>
</tr>
<tr>
<td>GHS 09</td>
</tr>
<tr>
<td>Signal Word</td>
</tr>
<tr>
<td>Danger</td>
</tr>
<tr>
<td>Hazard Statement Codes</td>
</tr>
<tr>
<td>H318: Causes serious eye damage.</td>
</tr>
<tr>
<td>H410: Very toxic to aquatic life with long lasting effects.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specific Concentration limits, M-Factors*</th>
</tr>
</thead>
<tbody>
<tr>
<td>M = 10 for Aquatic Acute 1</td>
</tr>
<tr>
<td>M = 10 for Aquatic Chronic 1</td>
</tr>
</tbody>
</table>

* proposal submitted to ECHA
b) Intended use, target species and effectiveness

DCPP is intended for disinfection of surfaces in hospitals and private areas by professional and non-professional users. The biocidal product contains 0.2% (w/w) DCPP and is diluted 1:50 with water to give the final cleaning solution (0.004% w/w final use concentration). Tasks like disinfection of surfaces by mopping (especially large areas) or manual wiping with a soaked cloth (especially small areas) are covered. Spraying and hot vapor applications are not assessed and out of scope. DCPP has at least bacteriostatic activity at the intended in-use concentrations of 0.004%.

The bactericidal efficacy of DCPP was shown in tests according to EN 1040 and EN 1276. According to these tests bactericidal efficacy was achieved against *Staphylococcus aureus*, *Pseudomonas aeruginosa* and/or *Escherichia coli* and *Enterococcus hirae* respectively. These tests showed that for concentrations below 0.02% w/w a.s. only bacteriostatic efficacy has been proven. In consequence at the intended in-use concentration of 0.004% the product can only be considered as having bacteriostatic activity.

Based on available literature information on triclosan showing that resistance in laboratory tests may be associated with changes in antibiotic susceptibility, resistance against DCPP and cross resistance with antibiotics cannot be excluded.

c) Overall conclusion of the evaluation including need for risk management measures

**Human health**

DCPP is classified for eye damage category 1. It is not classified for skin irritation, skin sensitization or acute toxicity. Genotoxicity was concluded as negative. Carcinogenicity and reproductive toxicity was evaluated on the basis of respective standard animal studies read across from triclosan and concluded as negative. The read across was supported by structural similarity, toxicokinetic studies and available toxicological data for both substances.

The table below summarises the exposure scenarios assessed.
<table>
<thead>
<tr>
<th>Scenario</th>
<th>Description of scenario</th>
<th>Exposed group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cleaning surfaces (primary)</td>
<td>Disinfection of surfaces is usually done by mopping (especially large areas) or manual wiping with a soaked cloth (especially small areas). The surface is then air-dried. The cleaning task is expected to be for 6 hours. The model also covers the dilution/mixing and loading phase. Dermal exposure of hands and body was considered, with the use of gloves. No further PPE applied. Exposure via inhalation is not expected.</td>
<td>Professionals</td>
</tr>
<tr>
<td>Cleaning surfaces (primary)</td>
<td>Non-professional use includes wiping of small surfaces as well as floor cleaning in private homes. Cleaning of surfaces is usually done by mopping or manual wiping with a soaked cloth. The surface is then air-dried. Dermal exposure exposure of hands and body. PPE is not used. Exposure via inhalation is not expected.</td>
<td>Non professionals</td>
</tr>
<tr>
<td>Exposure to treated surfaces (secondary)</td>
<td>Dermal and oral contact of infant, when they crawl over a floor after treatment.</td>
<td>General public</td>
</tr>
</tbody>
</table>

Disinfectant cleaner: all-purpose cleaner product is intended for the disinfectant cleaning of surfaces in hospitals and private areas. Exposure via the inhalation route is considered to be not relevant as no aerosols are formed during the expected activities and DCPP reveals a low volatility. Oral exposure to DCPP is considered to be unlikely for users (adults), when misuse is not considered. Therefore dermal contact is considered to be the only relevant source of exposure during application.

Secondary exposure is possible for infants via dermal and oral routes, i.e. hand-to-mouth contact with treated surfaces.

The risk for systemic effects with professionals appears clearly acceptable if tier 2 exposure estimates including the use of PPE are considered.

The risk to non-professionals for systemic effects is acceptable assuming one use per day without gloves and without protective clothing.

In conclusion the use of DCPP as surface disinfectant by professionals and non professional users is acceptable. Evaluation of the local effects of the final product may need to be performed at product authorisation, where appropriate.

**Environment**

The table below summarises the exposure scenarios assessed.
### Summary table: environment scenarios

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Description of scenario including environmental compartments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimicrobial active ingredient in surface disinfectants, which are intended for the cleaning of surfaces in hospitals and private areas by professional and non-professional users.</td>
<td>The professional use is cleaning and disinfection of large areas by cleaning personnel as well as wiping smaller surfaces by professional health care personnel. The non-professional use includes wiping of small surfaces as well as floor cleaning in private homes. Disinfection of surfaces is usually done by mopping (especially large areas) or manual wiping with a soaked cloth (especially small areas). The surface is then air-dried. The main emission pathway is the sewer system. Thus, only the sewage treatment plant will be the direct receiving compartment for DCPP emissions. Indirectly receiving compartments are surface water, sediment, soil and groundwater. The risk assessment was conducted for the active substance DCPP and its metabolite methyl-DCPP. In case of lack of data, data from read-across to triclosan and methyl-triclosan were used.</td>
</tr>
</tbody>
</table>

DCPP and its metabolite methyl-DCPP in PT2 pose in a higher tier calculation no unacceptable risks neither for microorganisms in STP, aquatic organisms in surface water and sediment, soil organisms nor for groundwater. Therefore, DCPP and its metabolite methyl-DCPP in PT2 products pose no unacceptable risks for any environmental compartment and in the food chains (secondary poisoning) are expected.

#### 2.2. Exclusion, substitution and POP criteria

##### 2.2.1. Exclusion and substitution criteria

The table below summarises the relevant information with respect to the assessment of exclusion and substitution criteria:

<table>
<thead>
<tr>
<th>Property</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMR properties</td>
<td>Carcinogenicity (C) Data available, evidence not sufficient for classification</td>
</tr>
<tr>
<td></td>
<td>Mutagenicity (M) Data available, evidence not sufficient for classification</td>
</tr>
<tr>
<td></td>
<td>Toxic for reproduction (R) Data available, evidence not sufficient for classification</td>
</tr>
<tr>
<td>PBT and vPvB properties</td>
<td>Persistent (P) or very Persistent (vP) DCPP and its metabolite, methyl-DCPP are not considered to fullfill the P or vP criterion.</td>
</tr>
<tr>
<td></td>
<td>Bioaccumulative (B) or very Bioaccumulative (vB) DCPP itself is not B, but its metabolite methyl-DCPP fulfils the vB-criterion.</td>
</tr>
</tbody>
</table>
Toxic (T)  | DCPP as well as its metabolite methyl-DCPP fulfil the T-criterion.  
---|---
Endocrine disrupting properties  | DCPP is not considered as endocrine disruptor according to the interim criteria.

Consequently, the following is concluded:
DCPP does not meet the exclusion criteria laid down in Article 5 of Regulation (EU) No 528/2012.

DCPP does meet the conditions laid down in Article 10 of Regulation (EU) No 528/2012, and is therefore considered as a candidate for substitution by being a substance for which two of the three PBT criteria (according to annex XIII of REACH, EC No. 1907/2006) are met, as the metabolite methyl-DCPP fulfils the T-criterion and the vB-criterion. However, further data is required to conclude on the P criterion (see 2.4 and 2.5). The exclusion and substitution criteria were assessed in line with the "Note on the principles for taking decisions on the approval of active substances under the BPR"¹ and in line with "Further guidance on the application of the substitution criteria set out under article 10(1) of the BPR"² agreed at the 54th and 58th meeting respectively, of the representatives of Member States Competent Authorities for the implementation of Regulation 528/2012 concerning the making available on the market and use of biocidal products. This implies that the assessment of the exclusion criteria is based on Article 5(1) and the assessment of substitution criteria is based on Article 10(1)(a, b, d, e and f).

No comments were received during public consultation.

2.2.2. POP criteria
The POP criteria are listed in Annex D of the Stockholm Convention. One important element of these criteria is long-range transport. No monitoring data distant from source regions are available for DCPP. The half-life of DCPP in the troposphere was calculated to be 0.821 days. For the metabolite methyl-DCPP the calculated half-life is 1.17 days according to the AOP Program (v1.92) (24-hr day; 5x10⁵ OH/cm³). DCPP and methyl-DCPP are not considered to undergo long-range transport.

Therefore it can be concluded that DCPP will not fulfill the Annex D POP screening criteria of the Stockholm Convention.

2.3. BPC opinion on the application for approval of the active substance DCPP in product type 2
In view of the conclusions of the evaluation, it is proposed that 5-Chloro-2-(4-chlorophenoxy)-phenol (DCPP) shall be approved and be included in the Union list of approved active substances, subject to the following specific conditions:

1. Specification: minimum purity of the active substance evaluated: 995 g/kg w/w.

2. The active substance contains polychlorinated dibenzo-p-dioxins and

---

¹ See document: Note on the principles for taking decisions on the approval of active substances under the BPR (available from https://circabc.europa.eu/d/a/workspace/SpacesStore/c41b4ad4-356c-4852-9512-62e72cc919df/CA-March14-Doc.4.1%20-%20Final%20-%20Principles%20for%20substance%20approval.doc)

² See document: Further guidance on the application of the substitution criteria set out under article 10(1) of the BPR (available from https://circabc.europa.eu/d/a/workspace/SpacesStore/dbac71e3-cd70-4ed7-bd40-fc1cb92cfe1c/CA-Nov14-Doc.4.4%20-%20Final%20-%20Further%20guidance%20on%20Art10(1).doc)
polychlorinated dibenzofurans (PCDD/F) as impurities. The maximum limit for PCDD/F is set to 2 pg TEQ_{WHO-2005}/g.

3. DCPP is considered a candidate for substitution in accordance with Article 10(1)(d) of Regulation (EU) No 528/2012.

4. The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.

5. For professional users, safe operational procedures and appropriate organizational measures shall be established. Only where exposure cannot be reduced to an acceptable level by other means, products shall be used with appropriate personal protective equipment.

The following provision was proposed for treated articles by some members of the BPC to be added in the decision making process in Article 9(1) of the BPR: “DCPP must not be used in treated articles unless the efficacy and the benefits of the treated articles can be clearly demonstrated.”

The active substance does not fulfil the criteria according to Article 28(2)(a) and 28(2)(b) to enable inclusion in Annex 1 of Regulation (EU) 528/2012.

2.4. Elements to be taken into account when authorising products

1. The active substance DCPP is considered as a candidate for substitution, and consequently the competent authority shall perform a comparative assessment as part of the evaluation of an application for either national or Union authorisation.

2. Whilst the efficacy data provided is sufficient to recommend approval of the substance, data demonstrating the efficacy of the product at the minimum application rate against the range of proposed target organisms using the recommended application equipment must be provided at the product authorisation stage. In case bactericidal efficacy will be claimed additional data at product authorisation stage has to be submitted, as only bacteriostatic efficacy could be shown. Efficacy should be tested under relevant practical conditions (e.g. realistic contact time, high level soiling conditions), both in phase 2/step 1 tests and in phase 2/step 2 tests. If relevant, tests to prove long lasting antimicrobial activity have to be submitted.

3. A qualitative local risk assessment will be necessary if the biocidal product is classified for local effects.

4. The potential resistance of bacteria to DCPP could be of concern and, as such, resistance management measures should be included in the authorisation of products. These could include (but should not be restricted to) the following factors:

5. an indication in the accompanying leaflet of the of biocidal products warning: “Microbial resistance to DCPP and cross resistance with antibiotics can not be excluded”

6. and recommendation for a resistance management strategy such as: “Alternate DCPP containing products with other products which contain an active substance with a different mode of action, to prevent development of resistance due to prolonged use. Sub-inhibitory DCPP concentrations – which may originate through dilution effects- should be avoided.”
7. The results of the substance evaluation according to REACH for triclosan with the special concerns of endocrine disrupting properties and PBT/vPvB properties as well as other upcoming data have to be taken into account. According to the decision on substance evaluation pursuant to Article 46(1) of Regulation (EC) No 1907/2006 the Registrant(s) shall submit to ECHA by 26 September 2016 an update of the registration dossier containing the information required by this decision (pursuant to Article 46(2) of the REACH Regulation, see http://echa.europa.eu/documents/10162/0fe59e36-9bdb-4e08-a9ef-7cb01c8a4477)

After receiving the data the evaluating Member State (the Netherlands) has one year to assess the data. In this time period of one year the PBT EG or ED EG can be asked for advice.

8. Based on the available information it cannot be excluded that resistance against DCPP and cross resistance with antibiotics may occur. Therefore the occurrence of resistance of microorganisms against DCPP should be assessed. Periodic monitoring for resistant/less susceptible microorganisms to DCPP should be carried out, especially in health care areas, within the framework of routine hygiene controls in order to ensure that the target organisms remain susceptible to in-use concentrations of DCPP.

2.5. Requirement for further information

Sufficient data have been provided to verify the conclusions on the active substance, permitting the proposal for the approval of DCPP. However, further data shall be required as detailed below:

1. At the product authorisation stage validation data should be submitted showing that the analytical methods for active substance residues in water and soil are able to satisfy the required LOQ, i.e. 0.1 µg/L for water and 1µg/kg for soil. The data should be provided as soon as possible and at the latest 6 months before the date of approval to the evaluating Competent Authority (Austria).

2. The submitted photolysis studies did not identify all degradation products. Having in mind the structure of DCPP, formation of dioxins represents a potential concern. Referring to the found formation pathways of metabolites of DCPP, most relevant reactions are considered to be: dechlorination, condensation and ring opening of DCPP. Some of the detected unidentified degradation products were photolytically instable and were degraded shortly after formation. They are not considered to be relevant. Referring to the 2 more stable and unidentified metabolites reaching their maxima at the end of testing, evaluation of available data led to the conclusion that in this case it is very unlikely that they could be higher chlorinated dioxins. Nevertheless, the missing identity of the unidentified degradation products needs to be clarified. This information needs to be provided as soon as possible and at the latest 6 months before the date of approval to the evaluating Competent Authority (Austria).

3. The applicants used “dummy” products as part of their submission. Further data may be required, in particular regarding the physical and chemical properties, efficacy and dermal absorption of the products and should be provided by applicants at the product authorization stage.

In addition, further data will need to be provided at renewal of the active substance approval:
1. The applicant for the active substance should keep up to date with the scientific progress concerning development and spread of microbial resistance related to DCPP and cross resistance with antibiotics. This is considered necessary, because DCPP is used in healthcare systems and on the other hand the wide-spread diffuse use of the active substance may have an impact on the transfer of resistance to healthcare areas. At active substance renewal stage the applicant should submit an updated literature review and respective monitoring data for resistant/less susceptible microorganisms to DCPP, if available. In addition information about Triclosan is also considered relevant and should be included.

2. As Triclosan including its metabolite methyl-Triclosan is currently assessed under substance evaluation according to REACH with the special concerns of endocrine disrupting properties and PBT/vPvB properties and many data are from read across studies to Triclosan, the results of this substance evaluation according to REACH have to be taken into account. In any case, at the renewal stage for the re-evaluation of the persistence criterium of the metabolite methyl-DCPP at least a surface water simulation test (OECD Test Guideline No. 309: Aerobic Mineralisation in Surface Water - Simulation Biodegradation Test, performed at 12°C) with methyl-DCPP or the read across substance methyl-triclosan or a water sediment study (OECD Test Guideline No. 308: Aerobic and anaerobic transformation test in aquatic sediment systems surface water simulation test (OECD Test Guideline No. 309: Aerobic Mineralisation in Surface Water - Simulation Biodegradation Test) with methyl-DCPP needs to be available at the time point of re-evaluation. The applicant needs to consult with the eCA in due time prior the renewal stage on this issue: The eCA needs to have enough time to potentially consult the PBT expert group on this matter.

00o